Benchmark analyst Bruce Jackson upgraded NeoGenomics to Buy from Hold with a $20 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NEO:
- Here’s Why NeoGenomics’ (NASDAQ:NEO) Q4 Results Thrilled Investors
- NeoGenomics sees 2023 revenue $545M-$555M, consensus $545.08M
- NeoGenomics reports Q4 adjusted EPS (6c), consensus (16c)
- NeoGenomics announces results from study of RaDaR assay
- Needham upgrades NeoGenomics to Buy amid revenue and margin growth